Lexaria Bioscience Corp.
LEXX
$0.62
$0.000.36%
NASDAQ
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 0.00% | |||
| SG&A Expenses | 17.69% | -36.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.59% | -32.50% | |||
| Operating Income | 36.42% | 34.01% | |||
| Income Before Tax | 40.84% | 28.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.77% | 28.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 78.57% | -6.67% | |||
| Net Income | 40.83% | 28.85% | |||
| EBIT | 36.42% | 34.01% | |||
| EBITDA | 36.55% | 34.04% | |||
| EPS Basic | 45.82% | 33.51% | |||
| Normalized Basic EPS | 41.75% | 38.44% | |||
| EPS Diluted | 45.82% | 33.51% | |||
| Normalized Diluted EPS | 41.75% | 38.44% | |||
| Average Basic Shares Outstanding | 9.19% | 6.98% | |||
| Average Diluted Shares Outstanding | 9.19% | 6.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||